Drug intelligence / Profile preview

USM301

Development stage: Preclinical
Lead developer: Uscare Pharm
Modality: Nanoparticles → Drug Delivery Systems
Administration: Parenteral

Overview

USM301 is a discovery-stage drug delivery system (DDS) material and platform developed by Uscare Pharm. It is categorized under the company's "Material Innovation" and "Platform Innovation" pipelines, which focus on the development of advanced biomaterials to optimize the pharmacokinetic and pharmacodynamic properties of therapeutic agents. Uscare Pharm specializes in utilizing biocompatible polymers, such as hyaluronic acid (HA) derivatives, to create delivery vehicles that facilitate controlled release and targeted administration. While specific therapeutic targets or payloads associated with USM301 have not been publicly disclosed, the platform is intended to serve as a foundational technology for enhancing the delivery of various pharmaceutical compounds.

Other names: USM301 (Material)

Beyond the preview

Go deeper on USM301.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on USM301.

Explore the full profile